Silence Therapeutics
在场
Silence Therapeutics 是一家在股票代码 SLN (GB) 下上市的公司。
高管
查看带有其 15 名主要高管的组织结构图
Silence Therapeutics 搜索最多的简介
- Craig Tooman, President and Chief Executive Officer
- Ian Ross, Non-Executive Chairman of the Board
- Dave Lemus, Non-Executive Director
高管在Silence Therapeutics变化
- Gianine Esposito已作为Chief Human Resources Officer加入公司 (新闻发布的2024八月18号).
创建提醒
跟踪 Silence Therapeutics 的高管变动
药店
Silence Therapeutics 拥有 1,834 家竞争者，其中包括 Pfizer (美国(美洲))、Eli Lilly (美国(美洲)) 和 Roche (瑞士)。
Popular M&A news in 药店
- Clario 已收购 NRx Pharmaceuticals (公布2025三月18号).
- Knight Therapeutics has announced the acquisition of Paladin Labs (公布2025三月12号).
- Jazz Pharmaceuticals 已收购 Chimerix (公布2025三月6号).
药店 行业的其他推荐联系人
消息
Silence Therapeutics 的最新新闻稿
- Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
- Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
- Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
- Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
- Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
- Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
- Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
- Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
- Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
- View more press releases Close
